Nyxoah תפרסם את התוצאות הכספיות לרבעון הרביעי ולשנת הכספים 2024 ב-13 במרץ 2025

מונט-סנט-גיברט, בלגיה, 10 במרץ 2025, (GLOBE NEWSWIRE) :

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ("Nyxoah" או "החברה"), חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה בשינה (OSA) באמצעות נוירומודולציה, הודיעה היום כי החברה תפרסם את התוצאות הכספיות לרבעון הרביעי ולשנת הכספים 2024 ביום חמישי, 13 במרץ 2025. הנהלת החברה תקיים שיחת ועידה לדיון בתוצאות הכספיות באותו יום החל מהשעה 13:00 CET / 08:00 ET.

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2024 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2024 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah
John Landry, Chief Financial Officer 
[email protected]

For Media
In United States
FINN Partners – Fern Lazar
[email protected]

In Belgium/France
Backstage Communication – Gunther De Backer [email protected]

In International/Germany
MC Services – Anne Hennecke [email protected]

Attachment

• ENGLISH_Earnings Call 4Q24Save-The-Date FINAL

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire